Vanguard Fiduciary Trust
CGTX icon

Vanguard Fiduciary Trust’s Cognition Therapeutics CGTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$584K Buy
508,220
+44,536
+10% +$52.7K ﹤0.01% 3223
2026
Q1 		$352K Buy
+463,684
New +$540K ﹤0.01% 3328

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Vanguard Fiduciary Trust's CGTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cognition Therapeutics (CGTX) stake by 9.6% in Q2 2026, buying an estimated $52.7K and bringing the position to 508,220 shares worth $584K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Vanguard Fiduciary Trust first reported a position in CGTX in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 508,220 shares of Cognition Therapeutics worth $584K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 44,536 Cognition Therapeutics shares in Q2 2026, an estimated $52.7K.
  • Cognition Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3223 holding.
  • Vanguard Fiduciary Trust first reported a position in Cognition Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.